Regentis Biomaterials (RGNT) Income Statement: Revenue & Earnings

Regentis Biomaterials Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Regentis Biomaterials Ltd. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	0.00	0.00	0.00	0.00	0.00
Cost of Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00
Operating Expenses
Research & Development	-1.64	0.81	0.97	0.34	0.33
Selling, General & Administrative	0.71	1.13	0.44	0.33	0.03
Operating Expenses	-0.93	1.93	1.41	0.67	0.36
Operating Income	0.93	-1.93	-1.41	-0.67	-0.36
Other Income/Expense
Interest Income	0.00	0.00	0.00	0.00	0.00
Interest Expense	0.17	0.17	0.00	0.00	0.00
Other Income/Expense	4.04	-2.03	0.36	-0.01	-0.09
Income
Income Before Tax	4.80	-4.13	-1.45	-5.14	-0.41
Income Tax Expense	0.00	0.00	0.00	0.00	0.00
Net Income	4.80	-4.13	-1.45	-5.14	-0.41
Net Income - Continuous Operations	4.80	-4.13	-1.45	-5.14	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	4.97	-3.96	-1.45	-0.67	0.00
EBIT	4.97	-3.96	-1.45	-0.67	-0.36
Depreciation & Amortization	0.00	0.00	0.00	0.00	0.00
Earnings Per Share
Basic EPS	1.00	-1.00	-	-1.00	-3.00
Diluted EPS	1.00	-1.00	-	-1.00	-3.00
Basic Shares Outstanding	4.93	4.93	4.93	4.93	0.16
Diluted Shares Outstanding	4.93	4.93	4.93	4.93	0.16